CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 20 target
Drug / intervention
Following 3 or 4 cycles of systemic neoadjuvant chemotherapy and complete interval CC-0 surgery, patients in the study will receive 4 cycles of 21 days every 3 weeks of the regimen studied by Armstrondrug
Likely dose
Following 3 or 4 cycles of systemic neoadjuvant chemotherapy and complete interval CC-0 surgery, patients in the study will receive 4 cycles of 21 days every 3 weeks of the regimen studied by Armstron 175 mgfrom record
Key inclusion· 7
  • ✓Age 18-70 years
  • ✓FIGO stage IIIB-C/IV epithelial ovarian cancer (high-grade serous)
  • ✓No extraperitoneal disease
  • ✓Neoadjuvant chemotherapy with 3 or 4 systemic cycles
Key exclusion· 10
  • ✕Disease progression during neoadjuvant chemotherapy
  • ✕Extraperitoneal disease including retroperitoneal lymph node metastases
  • ✕Inability to achieve CC0 cytoreduction
  • ✕At least one digestive anastomosis of any type

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06902467
NCT06902467N/ARecruitingMonitorUpdated 15mo ago · Completion was 3mo ago
Slow Enrollment
Long Recruiting
Monitor
CompareCT.gov

Combined Intraperitoneal Chemotherapy Regimen After Optimal Interval Surgery in Advanced Ovarian Cancer: BICOV-1 (Bidirectional Chemotherapy in Ovarian Cancer)

Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia·interventional·Posted Mar 30, 2025·Updated Mar 30, 2025

In Brief

A clinical study evaluating Following 3 or 4 cycles of systemic neoadjuvant chemotherapy and complete interval CC-0 surgery, patients in the study will receive 4 cycles of 21 days every 3 weeks of the regimen studied by Armstron for Ovarian Cancer. Currently recruiting, targeting 20 participants across 1 site.

Signals

Enrolling slower than its timeline implies

Detailed Summary

A multicenter, low-intervention, drug-based study to evaluate the feasibility and safety of a combined regimen of two intraperitoneal chemotherapy modalities (used in routine clinical practice) following interval surgery for the treatment of advanced ovarian cancer. This is an independent research project (free of commercial interests).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesSpain
Collaborators--

Timeline

N/ARecruiting
2024202520262027
First PostedMar 30, 2025
Enrollment StartFeb 27, 2023
Primary CompletionMar 15, 2026
Study CompletionDec 15, 2026
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 1.3 years ago

Interventions

Following 3 or 4 cycles of systemic neoadjuvant chemotherapy and complete interval CC-0 surgery, patients in the study will receive 4 cycles of 21 days every 3 weeks of the regimen studied by Armstrondrug

Following 3 or 4 cycles of systemic neoadjuvant chemotherapy and complete interval CC-0 surgery, patients in the study will receive 4 cycles of 21 days every 3 weeks of the regimen studied by Armstrong 8 and modified by GEICO 18: IV paclitaxel 175 mg /m2 (day 1) + IP cisplatin 100 mg/m2 (day 2) + IP paclitaxel 60 mg/m2 (day 8).